Cambridge, United Kingdom

Richard Charles Alfred Sainson

USPTO Granted Patents = 5 

Average Co-Inventor Count = 9.6

ph-index = 1

Forward Citations = 16(Granted Patents)


Company Filing History:


Years Active: 2018-2025

Loading Chart...
5 patents (USPTO):

Title: The Innovative Contributions of Richard Charles Alfred Sainson

Introduction: Richard Charles Alfred Sainson is an esteemed inventor based in Cambridge, GB. His significant contributions to the field of immunology and antibody development have led to the acquisition of four patents, showcasing his immense talent and dedication to advancing medical science.

Latest Patents: Sainson's latest innovations include groundbreaking work on anti-ICOS antibodies. These antibodies specifically bind to ICOS (Inducible T cell Co-Stimulator) and are designed for therapeutic applications aimed at modulating the ratio between regulatory T cells and effector T cells. This research holds potential for stimulating the immune systems of patients, particularly in the treatment of cancers. Another notable patent features a bispecific antibody that targets both ICOS and PD-L1, comprising an ICOS-binding Fab region and a PD-L1-binding Fcab region. This multispecific antibody is intended for use in immuno-oncology, especially for treating solid tumors through combination therapy with other immune checkpoint molecules such as PD-1 and CTLA-4.

Career Highlights: Sainson currently works with Kymab Limited, a company recognized for its pioneering efforts in the development of therapeutic antibodies. His role within the company allows him to further hone his expertise in antibody engineering while contributing to significant advancements in cancer treatment and immunotherapy.

Collaborations: Throughout his career, Sainson has collaborated with talented professionals such as Stephen John Arkinstall and Jamie Iain Campbell. These collaborations have been instrumental in expanding the scope of research and leading to innovative solutions in the field of biomedicine.

Conclusion: Richard Charles Alfred Sainson is a remarkable inventor whose work in antibody research is pushing the boundaries of medical science. His dedication to innovation not only highlights his expertise but also underscores the importance of collaborative efforts in the advancement of therapeutic technologies. The impact of his patents is poised to facilitate new treatment avenues for patients battling various forms of cancer, reaffirming the critical role of inventors in shaping the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…